{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:49:14Z","timestamp":1771231754953,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-024-01931-7","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:21:38Z","timestamp":1732083698000},"page":"132-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT\/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-4654","authenticated-orcid":false,"given":"Matthew S.","family":"Robertson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SuChun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyesun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahar","family":"Glomski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Kilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atish D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"1931_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40336-016-0196-5","volume":"4","author":"GJ Cook","year":"2016","unstructured":"Cook GJ, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging 4:439\u2013447","journal-title":"Clin Transl Imaging"},{"key":"1931_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195\u2013202","journal-title":"Cancer"},{"key":"1931_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RLU.0b013e3182392bd0","volume":"37","author":"BL Franc","year":"2012","unstructured":"Franc BL, Myers R, Pounds TR et al (2012) Clinical utility of SPECT-(low-dose)CT versus SPECT alone in patients presenting for bone scintigraphy. Clin Nucl Med 37:26\u201334","journal-title":"Clin Nucl Med"},{"key":"1931_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00259-009-1334-3","volume":"37","author":"V Helyar","year":"2010","unstructured":"Helyar V, Mohan HK, Barwick T et al (2010) The added value of multislice SPECT\/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 37:706\u2013713","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1931_CR5","doi-asserted-by":"publisher","first-page":"7039406","DOI":"10.1155\/2017\/7039406","volume":"2017","author":"O Rager","year":"2017","unstructured":"Rager O, Nkoulou R, Exquis N et al (2017) Whole-body SPECT\/CT versus planar bone scan with targeted SPECT\/CT for metastatic workup. Biomed Res Int 2017:7039406","journal-title":"Biomed Res Int"},{"key":"1931_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13550-020-00659-5","volume":"10","author":"N Miyaji","year":"2020","unstructured":"Miyaji N, Miwa K, Tokiwa A et al (2020) Phantom and clinical evaluation of bone SPECT\/CT image reconstruction with xSPECT algorithm. EJNMMI Res 10:71","journal-title":"EJNMMI Res"},{"key":"1931_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-017-0024-9","author":"I Duncan","year":"2018","unstructured":"Duncan I, Ingold N (2018) The clinical value of xSPECT\/CT Bone versus SPECT\/CT. A prospective comparison of 200 scans. Eur J Hybrid Imaging. https:\/\/doi.org\/10.1186\/s41824-017-0024-9","journal-title":"Eur J Hybrid Imaging"},{"key":"1931_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13550-016-0217-4","volume":"6","author":"M Beck","year":"2016","unstructured":"Beck M, Sanders JC, Ritt P et al (2016) Longitudinal analysis of bone metabolism using SPECT\/CT and (99m)Tc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. EJNMMI Res 6:60","journal-title":"EJNMMI Res"},{"key":"1931_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fmed.2019.00342","volume":"6","author":"R de Laroche","year":"2019","unstructured":"de Laroche R, Bourhis D, Robin P et al (2019) Feasibility study and preliminary results of prognostic value of bone SPECT-CT quantitative indices for the response assessment of bone metastatic prostate carcinoma to abiraterone. Front Med (Lausanne) 6:342","journal-title":"Front Med (Lausanne)"},{"key":"1931_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.119.240408","volume":"62","author":"H Dittmann","year":"2021","unstructured":"Dittmann H, Kaltenbach S, Weissinger M et al (2021) The prognostic value of quantitative bone SPECT\/CT before (223)Ra treatment in metastatic castration-resistant prostate cancer. J Nucl Med 62:48\u201354","journal-title":"J Nucl Med"},{"key":"1931_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12891-019-3001-6","volume":"20","author":"F Tabotta","year":"2019","unstructured":"Tabotta F, Jreige M, Schaefer N et al (2019) Quantitative bone SPECT\/CT: high specificity for identification of prostate cancer bone metastases. BMC Musculoskelet Disord 20:619","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"1931_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","volume":"12","author":"AD Choudhury","year":"2024","unstructured":"Choudhury AD, Kwak L, Cheung A et al (2024) Randomized phase II study evaluating the addition of pembrolizumab to radium-223 In metastatic castration-resistant prostate cancer. Cancer Immunol Res 12(6):704\u2013718","journal-title":"Cancer Immunol Res"},{"key":"1931_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1931_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"1931_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41824-017-0006-y","volume":"1","author":"I Kuji","year":"2017","unstructured":"Kuji I, Yamane T, Seto A et al (2017) Skeletal standardized uptake values obtained by quantitative SPECT\/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging 1:2","journal-title":"Eur J Hybrid Imaging"},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12880-021-00569-5","volume":"21","author":"N Qi","year":"2021","unstructured":"Qi N, Meng Q, You Z et al (2021) Standardized uptake values of (99m)Tc-MDP in normal vertebrae assessed using quantitative SPECT\/CT for differentiation diagnosis of benign and malignant bone lesions. BMC Med Imaging 21:39","journal-title":"BMC Med Imaging"},{"key":"1931_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2214\/ajr.132.6.927","volume":"132","author":"JJ Pollen","year":"1979","unstructured":"Pollen JJ, Shlaer WJ (1979) Osteoblastic response to successful treatment of metastatic cancer of the prostate. AJR Am J Roentgenol 132:927\u2013931","journal-title":"AJR Am J Roentgenol"},{"key":"1931_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/21681805.2014.982169","volume":"49","author":"R Nome","year":"2015","unstructured":"Nome R, Hernes E, Bogsrud TV et al (2015) Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol 49:211\u2013217","journal-title":"Scand J Urol"},{"key":"1931_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bco2.43","volume":"2","author":"Y Miyoshi","year":"2021","unstructured":"Miyoshi Y, Tsutsumi S, Kawahara T et al (2021) Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223. BJUI Compass 2:24\u201330","journal-title":"BJUI Compass"},{"key":"1931_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41391-019-0151-4","volume":"22","author":"JM Mota","year":"2019","unstructured":"Mota JM, Armstrong AJ, Larson SM et al (2019) Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prost Cancer Prost Dis 22:522\u2013530","journal-title":"Prost Cancer Prost Dis"},{"key":"1931_CR21","doi-asserted-by":"publisher","first-page":"100082","DOI":"10.1016\/j.esmoop.2021.100082","volume":"6","author":"DPVU Petrylak","year":"2021","unstructured":"Petrylak DPVU, Patel KR et al (2021) A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate\/prednisone or enzalutamide. ESMO Open 6:100082","journal-title":"ESMO Open"},{"key":"1931_CR22","doi-asserted-by":"publisher","first-page":"24320","DOI":"10.1038\/s41598-021-03853-0","volume":"11","author":"T Yamane","year":"2021","unstructured":"Yamane T, Takahashi M, Matsusaka Y et al (2021) Satisfied quantitative value can be acquired by short-time bone SPECT\/CT using a whole-body cadmium-zinc-telluride gamma camera. Sci Rep 11:24320","journal-title":"Sci Rep"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01931-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:56:24Z","timestamp":1741348584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01931-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01931-7","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR: none, YW: none, SC: none, HP: none, SG: none, LCH: reports previous employment at Dana-Farber Cancer Institute and\u00a0grants to institution from Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon\/Valient, Jannsen, Medivation\/Astellas, Genentech, Pfizer, and Endocyte (Novartis), Advisory or consulting services for Bayer, Genentech, Pfizer, Medivation\/Astellas, Corvus, Merck, Exelixis, Novartis, Advanced Accelerator Applications, Jounce, Bristol-Myers Squibb, EMD Serrano, Michael J Hennessy Associates (Healthcare Communications Company and several brands such as OncLive and PER), ASIM CME, and Ology Medical Education\u00a0during the conduct of the study, as well as current employment (including stock options) at Surface Oncology\u00a0and travel support form Bayer and Genentech outside the submitted work. AP: Consulting: Seagen Inc and Astellas Pharma Inc. JK: none, MF: none, LG: none, ADC: Advisory Board: Clovis, Dendreon, Bayer, Eli Lilly, AstraZeneca, Astellas, Blue Earth, Janssen, Tolmar, Sanofi Aventis; Research Funding to Institution: Bayer, Pfizer; Honoraria for speaking engagement: Bayer, Pfizer, Lantheus, HJ: Research support: Blue Earth Diagnostics, Inc; Consulting: Advanced Accelerator Applications, Spectrum Dynamics; Royalties: Cambridge Publishing; Honoraria: Blue Earth Diagnostics, Inc., Munrol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in full concordance with Declaration of Helsinki principles and Good Clinical Practice and approved by the Dana-Farber Cancer Institute Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}